

Press Release

Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars

Accelerates Cipla's global lung leadership agenda

Mumbai, India, August 25, 2021: Cipla Limited (BSE: 500087 | NSE: CIPLA EQ, hereafter referred to as "Cipla"), a leading global pharmaceutical company and Kemwell Biopharma Private Limited, a leading biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced execution of a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space.

Under the terms of the agreement, the joint venture will leverage Cipla and Kemwell's complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of biopharmaceutical products. Cipla's respiratory prowess combined with Kemwell's expertise in biologics will accelerate bringing these essential products to market.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said: "This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership. Guided by our purpose of 'Caring for life' our partnership with Kemwell will help serve unmet needs of patients across the globe."

Anurag Bagaria, Chairman and Chief Executive Officer of Kemwell, said: "We are very excited about combining the strengths of Cipla's expertise in development and commercialisation of respiratory products and Kemwell's biologics capabilities. Through this JV, we aim to make cost-effective biotherapeutics available to more patients globally."

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT July'21) and is the 3rd largest in the pharma private market in South Africa (IQVIA MAT July'21). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), and [LinkedIn](#).

About Kemwell:

Kemwell is a leading biologics CDMO in Asia which provides services to global biopharmaceutical organizations for both clinical and commercial needs. Kemwell, located in Bangalore, India provides customers with high quality and cost-effective access for end-to-end services in development and manufacturing of all mammalian cell culture-based products. Kemwell's facilities consists of cGMP drug substance manufacturing suites with over 5000L bioreactor capacity, sterile fill and finish line for cGMP drug product manufacturing and development laboratories to support process and analytical development for protein therapeutics such as monoclonal antibodies, bi-specific antibodies and fusion proteins. Kemwell is currently manufacturing commercial drug substance, drug product and has worked on many R&D projects to support its customers during the development and clinical phase for both novel biologics and biosimilars. For more information, please visit www.kemwellbiopharma.com.

For queries, please contact:

CIPLA

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com

KEMWELL

Marketing & Corporate Communications

E-Mail: Pressrelease@kemwellpharma.com